




NewLink Genetics Corporation  
Investor Relations Department  
2503 South Loop Drive  
Ames, IA 50010  
United States

[Visit IR website](#)   
[Sign-up for Email alerts](#) 

## Company Profile

---

Founded in 1999, NewLink Genetics is an immuno-oncology company focused on discovering and developing novel products for the treatment of cancer. The drug discovery and development teams at NewLink Genetics are relentlessly pursuing a wide range of immuno-oncology portfolio candidates with the potential to change the oncology landscape. NewLink Genetics' portfolio includes two small-molecule product candidates currently in clinical development. These product candidates inhibit the IDO pathway, a key immuno-oncology target, and focus on breaking the immune system's tolerance to cancer.

## Press Releases [\[ View all \]](#)

---

*Sep 7, 2017*  
[Updated Data for Indoximod Plus KEYTRUDA® \(pembrolizumab\) Demonstrate Improvement of Response Rate for Patients with Advanced Melanoma](#)

*Aug 29, 2017*  
[NewLink Genetics to Participate in Upcoming Investor Conferences](#)

*Jul 28, 2017*  
[NewLink Genetics Reports Second Quarter 2017 Financial Results and Updates Indoximod Program](#)

*Jul 27, 2017*  
[NewLink Genetics Announces First Patient Dosed in Phase 1 Study of IDO Pathway Inhibitor NLG802](#)

*Jul 10, 2017*  
[NewLink Genetics Receives Notice of Allowance from USPTO Covering Indoximod Salts and Prodrugs](#)

## Upcoming Events [\[ View all \]](#)

---

*Sep 25–25, 2017 4:10 PM - 4:40 PM ET*  
[Cantor Fitzgerald Global Healthcare Conference](#)

## Financials [\[ View all \]](#)

---

[Second Quarter Financial Results](#)

*Mar 6, 2017*  
[Annual Report \(10-K\)](#)

*Mar 31, 2017*  
[Proxy Statement \(DEF 14A\)](#)

*Aug 3, 2017*  
[Quarterly Report \(10-Q\)](#)

*May 5, 2017*  
[Quarterly Report \(10-Q\)](#)

*Nov 8, 2016*  
[Quarterly Report \(10-Q\)](#)